Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: In vitro and in vivo activity of miR-92a–Locked Nucleic Acid (LNA)–Inhibitor against endometrial cancer

Fig. 4

In vivo effects of systemic administration of miR-92a-LNA-inhibitor. a Subsequent measurements of tumor volume showed significant differences between miR-92a-LNA-inhibitor, scramble control (LNA-i-miR-NC) and not treated animals (PBS), * vs. scramble - p-value < 0.05, # vs. PBS – p-value < 0.05; b Because cancer cells over-express epidermal growth factor receptor, a non-invasive IR fluorescent-labeled probe for evaluating tumor size in vivo using Li-COR Odyssey Infrared Imaging Detection System was utilized; scanning tumor images revealed markedly reduced fluorescence intensity in the inhibitor group suggestive of an attenuating effect; in addition, no visible metastatic sites or extensive infiltration were revealed in either group – graph of representative animals; c MiR–92a-3p expression in mice tissues - significant difference was observed in case of tumor (p = 0.027), kidney (p < 0.0001), liver (p < 0.0001) and close to significant difference in heart (p = 0.063); bars represent Δ Cq log mean averaged values ± SD; *p-value < 0.05

Back to article page